Table 2. Relationship between GSK-3β expression and clinicopathological features of endometrial carcinomas.

Variables	GSK-3β (− = 0, + = 1, ++ = 2, +++ = 3)				Total	PR (%)	X2	P value
	0	1	2	3
The pathology types							3.019	0.385
Endometrioid adenocarcinoma	86	46	7	2	141	39.01
The other pathology types	11	2	0	0	13	15.38
Age							1.131	0.790
< 55	46	24	2	1	73	36.99
≥ 55	51	24	5	1	81	37.04
BMI (WHO)							2.955	0.450
< 25	57	21	4	1	83	31.33
≥ 25	40	27	3	1	71	43.66
Diabetes							3.762	0.297
No	69	28	6	1	104	33.65
Yes	28	20	1	1	50	44.00
Hypertension							1.534	0.700
No	70	34	4	2	110	36.36
Yes	27	14	3	0	44	38.64
FIGO stages							14.592	0.006
I + II	90	34	5	1	130	30.77
III + IV	7	14	2	1	24	70.83
Pathology classification							22.641	0.006
Well + Mod	89	45	7	0	141	36.88
Poor	8	3	0	2	13	38.46
The depth of myometrial infiltration							8.698	0.026
< 1/2	74	30	6	0	110	32.73
≥ 1/2	23	18	1	2	44	47.73
Lymph node metastasis							7.226	0.065
Negative	92	45	6	1	144	36.11
Positive	5	3	1	1	10	50.00
ER							3.603	0.299
−	28	12	0	0	40	30.00
+	69	36	7	2	114	39.47
PR							3.546	0.289
−	23	14	0	0	37	37.84
+	74	34	7	2	117	36.75
Positive ascites cytology							4.879	0.182
Negative	68	35	5	0	108	37.04
Positive	29	13	2	2	46	36.96

Abbreviations: PR = positive rate; Bold represents for P < 0.05.